{"entity":{"id":"nct07441460","kind":"trial","name":"A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer","aka":[],"tldr":"A phase 3 trial testing HB1801 in HER2-positive breast cancer, now recruiting.","summary":"A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer is a phase 3 interventional study registered as NCT07441460, led by Shanghai JMT-Bio, and recruiting on the registry. Official title: A Randomised, Controlled, Open-label, Multicenter, Phase III Clinical Study to Evaluate the Efficacy and Safety of KN026 Combined With HB1801 and Chemotherapy Versus Trastuzumab Combined With Pertuzumab and Chemotherapy as Adjuvant Therapy in Resectable HER2-positive Breast Cancer. Planned enrolment is 1800 participants (estimated). The study started in 2026-03-06 and primary completion is expected in 2034-08-07. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT07441460","url":"https://clinicaltrials.gov/study/NCT07441460"}],"tags":["ctgov-ingest"],"related":[],"cancers":["breast-her2-positive","her2-positive-early-breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["hb1801","kn026"],"companies":["cspc"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07441460","phase":"3","setting":"A Randomized, Controlled, Open-label, Multicenter, Phase III Clinical Study to Evaluate the Efficacy and Safety of KN026 Combined With HB1801 and Chemotherapy Versus Trastuzumab Combined With Pertuzumab and Chemotherapy as Adjuvant Therapy in Resectable HER2-positive Breast Cancer","sponsor":"Shanghai JMT-Bio","started":"2026-03-06","startedType":"actual","enrolled":1800,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07441460/","neighbours":{"cancer":[{"id":"her2-positive-early-breast-cancer","kind":"cancer","name":"Early HER2-positive breast cancer","route":"/cancers/her2-positive-early-breast-cancer/"},{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"}],"drug":[{"id":"hb1801","kind":"drug","name":"HB1801","route":"/drugs/hb1801/"},{"id":"kn026","kind":"drug","name":"KN026","route":"/drugs/kn026/"}],"company":[{"id":"cspc","kind":"company","name":"CSPC Pharmaceutical Group","route":"/companies/cspc/"}]}}